New biologic agents: a critical appraisal.


Approval of infliximab for treatment of Crohn's disease in late 1998 was a landmark event in medical therapy for inflammatory bowel disease. This agent was the first of many promised biologic response modifiers investigated in the last half decade, a result of progress in recombinant and monoclonal technologies and improvements in large-scale production of… (More)